Starpharma Holdings Limited announced that Dr. Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022. Dr. Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President and General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.135 AUD | 0.00% | +3.85% | -20.59% |
04-08 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
03-18 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.59% | 36.28M | |
+25.97% | 661B | |
+26.74% | 566B | |
-6.65% | 352B | |
+19.35% | 332B | |
+3.35% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.22% | 145B |
- Stock Market
- Equities
- SPL Stock
- News Starpharma Holdings Limited
- Starpharma Holdings Limited Appoints Jeff Davies as Director